The therapy is commonly used in clinical practice to help manage symptoms related to systemic hormonal imbalance and growth deficits. The medication is applied across domains where additional symptomatic support is needed, primarily focusing on chronic conditions where functional stability becomes affected. The core therapeutic area is replacement for Growth Hormone Deficiency (GHD) in both pediatric and adult populations.

This replacement is also considered relevant for other conditions that impact growth and metabolism, including Turner syndrome, Prader-Willi syndrome, and growth failure secondary to chronic renal disease. The general benefit helps address growth deficits in children and may assist with maintaining physical functionality and body composition in adults. The treatment assists with maintaining functional stability and coping with symptoms like fatigue and reduced exercise capacity.

“The therapy is used to provide supportive relief that helps ease the overall symptom burden associated with hormonal insufficiency.”

Fact: Supportive Management for GHD Symptoms

Fact: Supportive Management for Body Composition Alterations and Functional Deficits

Regulatory References

1. European Medicines Agency (EMA) product information

The eligibility for Rastan, which contains somatropin, is defined by absolute prohibitions and specific patient status rules, according to official regulatory documentation.

Contraindications (Must Not Use)

Official labeling strictly prohibits the use of Rastan in populations with specific severe conditions:

• Active Malignancy: Patients who currently have an active tumor or cancer.
• Acute Critical Illness: Individuals suffering complications after major procedures like open heart surgery, abdominal surgery, or those with acute respiratory failure.
• Prader-Willi Syndrome (PWS) Conditional: Children with PWS who are severely obese or have existing severe respiratory impairment (due to the risk of sudden death).
• Diabetic Retinopathy: Patients diagnosed with active proliferative or severe non-proliferative diabetic eye disease.
• Closed Epiphyses: Pediatric patients whose growth plates (epiphyses) are closed must discontinue the medicine when it is used for growth promotion.

Restricted and Conditional Use

Use is not recommended for women who are pregnant or breastfeeding due to a lack of established safety data. Patients with a history of intracranial tumors or current signs of Intracranial Hypertension (IH) must have therapy discontinued if IH is confirmed. Additionally, untreated severe hypothyroidism must be addressed before starting Rastan.

Interactions with other medicines and products

Interactions involving Rastan (Somatropin) are primarily defined by its effects on metabolic pathways and hormonal axes, as documented in regulatory prescribing information.

Documented Interaction Patterns

Pharmacodynamic and Hormonal Interactions

• Pharmacologic Glucocorticoids: Co-administration of glucocorticoids at supraphysiologic doses may attenuate the growth-promoting effects of Somatropin.
• Antihyperglycemic Agents (e.g., Insulin): Rastan may decrease insulin sensitivity, necessitating an official requirement for the adjustment of insulin and/or other antihyperglycemic agent doses to maintain glucose control.
• Oral Estrogen: Women receiving oral estrogen replacement may require a larger dose of Rastan to achieve the intended clinical goal, with a corresponding dose reduction required if oral estrogen is discontinued.

Pharmacokinetic Interactions

• CYP450-Metabolized Drugs: Rastan may alter the clearance of compounds metabolized by Cytochrome P450 (CYP450) liver enzymes, potentially leading to reduced plasma concentrations of co-administered substrates, such as certain corticosteroids, sex steroids, and anticonvulsants.
• Glucocorticoids (Active Cortisol): Somatropin inhibits the enzyme 11β-Hydroxysteroid Dehydrogenase Type 1, which can result in reduced serum cortisol concentrations in patients.

Interaction Considerations in Specific Populations

• Glucocorticoid Replacement: Patients with hypoadrenalism receiving glucocorticoid replacement may require an increase in their maintenance or stress dose of glucocorticoid following the initiation of Rastan therapy.

How Rastan Works

The drug's mechanism involves modulation of specific biological processes within the cardiac myocytes. The action occurs via two distinct mechanistic domains: influence on electrophysiology and influence on cellular metabolism. This process results in alterations to physiological functions.

Selective Ion Channel Modulation

This domain describes the drug's main mechanistic focus: it acts as a selective inhibitor of the late inward sodium current left(I Na , L ight) in heart cells. Inhibition of this persistent ion flow alters the heart's electrical activity during the repolarization phase, initiating a cascade that limits subsequent cellular calcium left( Ca^2+ ight) accumulation.

Regulation of Cellular Calcium and Relaxation

Reduction of the late sodium current indirectly affects calcium ion homeostasis. By reducing the intracellular concentration of calcium, the mechanism modulates the stiffness of the heart muscle. This consequence is associated with decreased tension within the ventricular walls.

Myocardial Energy Metabolism

This mechanistic domain involves the modulation of the heart's substrate utilization. The drug influences energy production by shifting the preference toward glucose oxidation over fatty acid oxidation. This metabolic shift alters the ratio of energy substrate consumption, which affects the oxygen cost of energy production in cardiac tissue.

How to Use Rastan: Official Administration Guidelines

This information describes the official instructions for using Rastan. It does not include advice, clinical rationale, or safety information.

General Administration

Dosage and Procedural Rules

Starting and Maximum Dose: The typical starting dose is 10 mg once daily, though a 5 mg starting dose may be considered for specific populations, such as Asian patients, or those with predisposing factors for muscle issues. The general maximum daily dose is 40 mg, which is reserved for patients who do not achieve their treatment goal with the 20 mg dose.

Dose Adjustment: Upon starting therapy or increasing the dose, a patient's lipid levels should be assessed as early as 4 weeks to determine if a dosage adjustment is necessary to reach the treatment goal.

Specific Population Restrictions: For patients with severe kidney problems (severe renal impairment) who are not on hemodialysis, the recommended starting dose is 5 mg once daily, and the daily dose should not exceed 10 mg.

Rastan: Recent Clinical Evidence

Recent clinical research has investigated the use of Rastan (recombinant human growth hormone) primarily in pediatric populations for conditions related to growth failure, such as growth hormone deficiency (GHD) and Turner's syndrome (TS).

Phase 3 Trial Results: Primary Outcomes

Studies have assessed the compound's effect on linear growth, utilizing measures such as annualized growth velocity and changes in height Standard Deviation Scores (SDS). Clinical trials have reported findings related to changes in height and growth rate parameters over the study periods. Early research data noted findings from some participants shortly after beginning the studies.

Comparative Studies and Administration

Clinical research has focused on comparing outcomes between Rastan treatment and baseline data, as well as comparing different administration forms. Comparative research examined the use of the solution for subcutaneous injection against lyophilized powder forms, often finding similar outcomes in key growth markers. Researchers also assessed the effect of administration on the compound’s absorption in the body.

Long-Term Research and Tolerability

Long-term studies collected data related to adverse events for the compound, with monitoring periods extending up to two years or more in some cohorts. These reports contribute to the overall understanding of the compound's characteristics during extended use. Data collected suggested that adverse events were generally mild to moderate.

Pharmacological Research

Pharmacokinetic studies focused on the characteristics of the compound's behavior in the body, which involves the compound's concentration over time after administration. Pharmacodynamic research focused on the measurement of biomarkers, such as Insulin-like Growth Factor 1 (IGF-1) levels, in relation to the compound's use.

Rastan (Somatropin) requires precise storage and handling to maintain the stability of the hormone, as strictly defined by regulatory documents.

For disposal, used needles and cartridges must be placed immediately in an FDA-cleared sharps disposal container and must not be thrown into household trash or wastewater. Unused medicine must be disposed of according to local pharmaceutical waste requirements.